Two faculty members in the University of Maryland School of Pharmacy’s Department of Pharmaceutical Sciences (PSC) are working to create new therapeutic agents to treat a prevalent liver disease.
Yan Shu, MD, PhD, and Fengtian Xue, PhD, both associate professors of PSC, are continuing their longtime drug discovery collaboration through a five-year, nearly $2.7 million grant from the National Institutes of Health that could one day treat non-alcoholic steatohepatitis (NASH).
Nearly one in eight Americans are affected by NASH, a level of liver damage that can progress to cirrhosis or liver cancer. Currently, there are no approved drugs on the market to treat NASH, but Shu and Xue are working on new chemical compounds that have potential to become future treatments for the condition.
Read the full story on the School of Pharmacy's News Center.